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Abstract 
Background: This retrospective study aimed to investigate the prognostic significance of pretreatment lymphocyte‑
to‑monocyte ratio (LMR) in locally advanced cervical cancer and its effect on overall survival.
Methods: The usual blood routine test was quantitatively performed to detect LMR. Signal strengths of human 
papilloma virus (HPV) type DNA in detected cervical cancer samples using hybrid capture 2 were analyzed in relative 
light units (RLU) compared with 1 pg/mL of HPV type 16 DNA‑positive control (RLU/PC) samples. A total of 1.0 RLU/
PC (~1 pg/mL) was used as the threshold for a positive result. The HPV‑positive specimens were typed using reverse‑
hybridization line probe assay.
Results: The LMR and HPV DNA were found to be independent prognostic markers for 5‑year overall survival (OS) 
and progression‑free survival, respectively. Their joint detection may further enhance the predictive value for OS. In 
the positive HR (high risk)‑HPV DNA status subgroup, LMR had a positive effect on improved OS but not in the non‑HR 
HPV DNA status subgroup.
Conclusions: The LMR and HR‑HPV DNA status can be identified as independent prognostic factors. The different 
influences of LMR in combined chemoradiotherapy on survival may be related to HR‑HPV DNA status. The combined 
detection of LMR and HR‑HPV DNA status may contribute to screening prognosis.
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Background
Cervical cancer is the third most commonly diagnosed 
type of cancer and the fourth leading cause of cancer 
death in women, accounting for 8  % (275, 100) of total 
cancer deaths among female individuals in 2008 [1]. 
Chemoradiotherapy is considered as a standard treat-
ment option for patients with unresectable and locally 
advanced cervical carcinoma. The 5-year survival rate 
of advanced cervical carcinoma has been significantly 
improved owing to the application of concurrent chemo-
radiotherapy in recent years. However, local recurrence 
and distant metastasis are still the most common fail-
ure patterns for advanced cervical cancer. Once post-
treatment failure occurs, patients have weaker prognosis 
with 1-year survival rate of less than 20 % [2]. Despite this 
alarming fact, more efficient methods to predict prog-
nosis are still lacking. Therefore, a reliable and effective 
method must be explored to screen patients at high risk 
(HR) of poor prognosis, thus providing reasonable base-
ment for more tailored cancer therapy.
Inflammation has long been associated with the devel-
opment, progressive process, and long-time treatment 
outcomes of cancers. Pretreatment peripheral differ-
ential leukocytes (including neutrophil, lymphocyte, 
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and monocyte) are associated with prognosis of various 
malignancies, such as breast cancer [3], gastric cancer 
[4], acute lymphoblastic leukemia [5], lymphoma [6, 7], 
primary hepatocellular carcinoma [8], and nasopharyn-
geal carcinoma [9].
To date, only one study has examined the relationship 
between differential leukocyte levels and prognosis of 
patients with cervical cancer, but this study only investi-
gated the prognostic value of the neutrophil-to-lympho-
cyte ratio (NLR) in cervical cancer [10]. The prognostic 
significance of lymphocyte-to-monocyte ratio (LMR), 
which is calculated by dividing absolute lymphocyte 
count (ALC) by absolute monocyte count (AMC), in cer-
vical cancer has not been clarified. Pretreatment LMR 
has been reported to be a prognostic factor for clinical 
outcomes in non-cervical cancers, such as diffuse large B 
cell lymphoma, Hodgkin’s lymphoma, and nasopharyn-
geal carcinoma [6, 7, 9]. Therefore, we hypothesize that 
lymphocytes, monocytes, and LMR may also play an 
important role in cervical carcinoma. Previous stud-
ies have demonstrated that HPV DNA status is linked 
to prognosis in invasive cervical cancer [11]. However, 
whether the HPV DNA status has some influence on 
the prognosis of LMR level in cervical cancer remains 
unclear.
Therefore, we performed a retrospective study on 
the prognostic value of pretreatment LMR in locally 
advanced cervical carcinoma patients and then investi-
gated its correlation with HPV DNA status and the influ-
ence of HPV DNA status on the prognosis of LMR level 
in the disease. To the best of our knowledge, this is the 
first study on the association between LMR and progno-
sis of cervical carcinoma patients.
Patients and methods
Patients and general data
Patients with locally advanced cervical carcinoma, who 
were initially treated at the Sun Yat-sen University Can-
cer Center from January 2003 to December 2004, were 
enrolled in this study. Patient eligibility was based on 
the following inclusion criteria before treatment: (1) 
biopsy-confirmed cervical cancer of clinical stage IIb-
IVa according to the International Federation of Gyne-
cology and Obstetrics (FIGO) 2009 Staging System; (2) 
histological types that were squamous cell carcinoma 
(SCC) or adenocarcinoma (ADC) or their mixture in 
cervical carcinoma; (3) definitive radiotherapy com-
bined with chemotherapy in any sequence; (4) with 
complete clinical data; (5) performance status ranging 
from 0 to 2 based on the Eastern Cooperative Oncology 
Group system; (6) normal renal, cardiac and liver func-
tions; and (7) with sufficient pretreatment tumor biopsy 
specimens for measurement of HPV DNA levels before 
treatment.
The exclusion criteria were as follows: (1) distant 
metastasis under clinical examination or imaging at the 
time of diagnosis; (2) histological types that were not 
squamous cell carcinoma (SCC) or adenocarcinoma 
(ADC) or their mixture in cervical carcinoma; (3) previ-
ous chemotherapy; (4) previous radiotherapy to the pel-
vis region; (5) previous surgery on the primary tumor site 
before being enrolled in this study; (6) history of other 
malignant tumors or simultaneous multiple tumors; and 
(7) a positive pregnancy test result for women of child-
bearing age.
A total of 424 patients were enrolled in this study. 
Patient consent and approval from the Institute Research 
Ethics Committee were obtained prior to the use of these 
clinical materials for research purposes. The clinical 
characteristics of the locally advanced cervical carcinoma 
patients are described in detail in Table  1. The enrolled 
patients had a median age of 47 years (ranging from 18 
to 74 years). Clinical follow-up information was obtained 
from patient medical records.
All enrolled patients received any of the three treat-
ment modalities: inductive chemotherapy plus radia-
tion therapy (IC +  RT), concurrent chemoradiotherapy 
(CCRT), and inductive chemotherapy (IC) plus CCRT.
Treatment
Radiation
Images taken from computed tomography (CT) with 
immobilization tools were used to plan external beam 
radiation (EBRT) and brachytherapy. Each patient 
received EBRT using 6 MV photons with a 7-field inten-
sity modulated radiotherapy (IMRT) technique to spare 
some of the small bowels anterior to the iliac nodes. 
EBRT was administered to the whole pelvis for a total 
dose of 50 Gy. The daily fraction size was 2.0 Gy, which 
was administered five times per week for 5  weeks. 
High-dose rate intracavitary brachytherapy was started 
3–4  weeks after EBRT initiation. The median dose of 
24  Gy was delivered to point A with 4  Gy per fraction 
twice a week for 3  weeks. The total dose delivered to 
point A was equal to or greater than 85 Gy.
Chemotherapy
IC was administered 3 weeks per cycle for two or three 
cycles, with a combination of cisplatin (80  mg/m2) and 
paclitaxol (175  mg/m2). All concurrent chemotherapy 
regimens were cisplatin-based. Cisplatin (50  mg/m2) 
alone or a combination of cisplatin (30 mg/m2) and pacli-
taxol (135 mg/m2) was administered weekly for 5 weeks 
during EBRT, beginning on the first day of radiation.
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LMR measurement
Peripheral blood samples were obtained from the periph-
eral blood of patients after cervical cancer diagnosis and 
before the initiation of any treatment modality. Periph-
eral lymphocytes and monocytes were counted using 
the automated hematology analyzer Sysmex XE-2100 
(Sysmex, Japan). All patients had no self-reported acute 
infections or hematologic disorders, indicating that the 
cell counts can represent the normal baseline value. The 
peripheral LMR was calculated from the differential 
count by dividing ALC by AMC.
Detection of HPV DNA status
Paraffin wax-embedded blocks from 424 patients with 
locally advanced cervical cancer were collected. Depar-
affinization was performed with Xylene to prepare sam-
ples for DNA isolation, and DNA was retrieved using the 
Qiagen DNeasy Blood & Tissue Kit (Valencia, CA, USA). 
DNA was extracted using proteinase K digestion and 
then purified by a modified protocol using the Qiagen 
DNeasy Kit, as described by Steinau [12]. The extracted 
DNA was amplified using the PCR-SPF 10 (version 1) 
method. The signal strengths of HPV DNA in cervical 
cancer samples were detected using Hybrid Capture 2 
(HC2), a DNA enzyme immunoassay, and were analyzed 
in relative light units (RLU) compared with 1  pg/mL of 
HPV-type 16 DNA-positive control (RLU/PC) sam-
ples. A total of 1.0 RLU/PC (~1 pg/mL) was used as the 
threshold for a positive result.
Genotyping of positive HPV DNA
The HPV-positive specimens were typed using reverse-
hybridization line probe assay with 23 type-specific 
hybridization probes [13, 14]. We defined oncogenic 
HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 
68 as HR HPV type and HPV 6, 11, 42, 43, 81, and 83 as 
Table 1 Correlation of pretreatment LMR with clinicopathologic characteristics of patients with advanced cervical carci-
noma (n = 424)
LMR lymphocyte-to-monocyte ratio; HPV human papillomavirus; DNA deoxyribonucleic acid; SCC squamous cell carcinoma; Ag antigen; FIGO International Federation 
of Gynecology and Obstetrics; ADC adenocarcinoma; ASC adenosquamous carcinoma; IC inductive chemotherapy; CCRT concurrent chemoradiotherapy; RT radiation 
therapy; HR high risk
Characteristic No. of patients (%) Pretreatment LMR level p value HPV DNA status p value
High value  
(n = 260)







≤46 205 (48.35 %) 133 72 0.146 190 15 0.607
>46 219 (51.65 %) 127 92 200 19
HPV DNA
Positive 390 (91.98 %) 246 144 0.012 – – –
Negative 34 (8.02 %) 14 20 – –
Lymph node status classification
Node‑negative 277 (65.33 %) 212 65 0.001 252 25 0.295
Node‑positive 147 (34.67 %) 48 99 138 9
FIGO classification
IIA 86 (20.28 %) 41 45 0.0 22 81 5 0.803
IIB 84 (19. 81 %) 48 36 78 6
IIIA 92 (21.70 %) 63 29 83 9
IIIB 90 (21.23 %) 61 29 81 9
IVA 72 (16.98 %) 47 25 67 5
Pathological type
SCC 305 (71.93 %) 194 111 0.337 288 17 0.016
ADC 31 (7.31 %) 19 12 25 6
ASC 33 (7.78 %) 19 14 29 4
UDC 55 (12.97 %) 28 27 48 7
Treatment modality
IC + RT 143 (33.73 %) 83 60 0.607 132 11 0.984
CCRT 147 (34.67 %) 92 55 135 12
IC + CCRT 134 (31.60 %) 85 49 123 11
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low-risk (LR) HPV type [15, 16]. The possible HR and LR 
HPV types were reclassified as non-HR HPV types.
Follow-up and statistical analysis
Follow-up examination was performed approximately 
every 3 months for the first 2 years, every 6 months for 
the next 3  years, and every year thereafter. During the 
routine follow-up, imaging studies, including pelvic mag-
netic resonance imaging, thorax and abdomen CT, and 
bone scan using single photon emission CT, were per-
formed at the predetermined time. When tumor recur-
rence and/or distant metastasis was suspected based on 
clinical findings or imaging studies, biopsy of that lesion 
was performed on a case-by-case basis.
The observations ended on December 31, 2012. The 
assessed endpoints of this study were overall survival 
(OS) and progression-free survival (PFS). OS was char-
acterized by the time of the initial treatment to death 
from cervical carcinoma or the last follow-up visit. PFS 
was characterized by the last date of follow-up or the end 
date of observation from the initial treatment to distant 
metastasis or the relapse noted on images in patients who 
completely responded to treatment, and the locoregional 
or distant progression of disease in patients who partially 
responded.
These endpoints were analyzed and compared using 
the Kaplan–Meier method and log-rank test. Chi square 
test was used to compare qualitative variables. Univariate 
analysis was performed to determine the significance of 
variables using the Cox regression model for PFS and OS. 
Multivariate analyses with the Cox proportional hazards 
regression model was used to determine the independent 
prognostic factors. Spearman’s rank correlation test was 
used to evaluate the relationship between LMR level and 
HPV DNA status in terms of some clinical characteris-
tics. The statistical test was a two-sided test performed 
using SPSS 16.0 programs (SPSS Inc., Chicago, USA). A 
two-tailed p value <0.05 was considered significant.
Classification of the enrolled patients according to the 
detected HPV DNA status from pretreatment cancer tissue
According to the detected HPV DNA status from the 
pretreatment cancer tissue of patients with advanced cer-
vical carcinoma, the patients with positive HR HPV DNA 
were classified as the HR-positive HPV DNA group, 
whereas those with negative or low risk-HPV DNA were 
classified as the non-HR HPV group.
Selection of appropriate cut-off scores for PFS and OS
Receiver operating characteristic curve analysis was 
used to define the most appropriate cutoff value for 
absolute lymphocyte and monocyte counts and LMR 
to stratify patients at HR of malignancy-related death 
or progression, thereby avoiding the predetermined cut 
point. The score selected as the best cut-off value was the 




In this study involving 424 patients with unresectable 
advanced cervical carcinoma treated with chemoradio-
therapy, none had distant metastasis at the time of diag-
nosis. The median follow-up period was 73 months for all 
patients and 88  months for patients who did not die of 
their disease. A total of 129 patients (30.43  %, 129/424) 
had distant metastasis throughout the follow-up period, 
of which 52, 40, 25, and 12 developed bone metasta-
ses, lung metastases, liver metastases and distant lymph 
node metastases in the abdominal or thoracic cavity, 
respectively. Moreover, 80 patients developed recurrent 
disease at either local or regional lesion site; the local–
regional recurrence rate was 18.87 % (80/424). The 3- and 
5-year OS rates were 70.3 and 54.76  %, respectively. Of 
148 patients, 52 died from metastatic disease, 54 from 
recurrent and metastatic disease, and 42 from recurrent 
disease.
A total of 424 patients were eligible for this study. 
The optimal cut-off values of ALC, AMC, and LMR 
were 2.35 × 109/L (AUC = 0.674, 95 % CI 0.520–0.781, 
p =  0.028) with sensitivity of 77.73  % and specificity of 
72.4 %, 0.38 × 109/L (AUC = 0.515, 95 % CI 0.489–0.689, 
p = 0.043), and 5.28 (AUC = 0.778, 95 % CI 0.637–0.917, 
p =  0.013) with sensitivity of 85.37  % and specificity of 
75.40 %, respectively (Fig. 1a, b, c). Patients with HR-pos-
itive HPV DNA exhibited higher monocyte counts than 
those with non-HR HPV DNA(p < 0.01).
Correlation of LMR Level or HPV DNA status with clinical 
characteristics and their mutual relationship
Of the 424 patients with advanced cervical carcinoma, 
390 had HR-positive HPV DNA in the cancer tissue sam-
ples tested using HC2. As shown in Tables  1 and 2, no 
significant difference in the case of different ages and 
treatment modalities were found for pretreatment LMR 
Level and HPV DNA status, respectively. Moreover, the 
LMR level was not significantly different (p > 0.05) com-
pared with the WHO pathologic type. However, the 
LMR level was significantly different between different 
lymph node status classifications and FIGO classification 
(p  <  0.05), as summarized in Table 1. Contrary to LMR 
level, the HPV DNA status showed no significant rela-
tionship with lymph node status and FIGO classifications 
except with the WHO pathologic type (p < 0.01).
In this study, the LMR levels were closely associated 
with HPV DNA status. Most of the patients with high 
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LMR levels had HR-positive HPV DNA. The significant 
association between high LMR level and HR-positive 
HPV DNA rate was observed not only in terms of FIGO 
classifications IIA (r =  0.421, p =  0.000), IIB (r =  0.397, 
p  =  0.001), IIIA (r  =  0.571, p  =  0.000) and IIIB  +  IVA 
(r  =  0.720, p  =  0.000), but also on OS (r  =  0.361, 
p = 0.000) and PFS (r = 0.352, p = 0.026).
Prognostic implications of LMR level and HPV DNA status 
from pretreatment cancer tissue
The 5-year OS and PFS of patients in the high ALC 
(≥2.35 ×  109) and low ALC (<2.35 ×  109) groups were 
analyzed and found to be 82.2 and 64.2  % (p  =  0.008, 
Fig.  2a) and 77.2 and 56.9  % (p  =  0.002, Fig.  2b), 
respectively.
A significant difference was observed between the 
high AMC (≥0.38  ×  109) and low AMC (<0.38  ×  109) 
groups on 5-year PFS, with 79.5 and 71.8 %, respectively 
(p  =  0.035, Fig.  2d). However, no significant difference 
regarding the 5-year OS was found between the high 
AMC (≥0.38 × 109) and low AMC (<0.38 × 109) groups, 
with 75.5 and 71.5 %, respectively (p > 0.05, Fig. 2c).
The 5-year OS rates of the high LMR group (≥5.28) 
and low LMR group (<5.28) were analyzed using the he 
Kaplan–Meier survival analysis and were found to be 
75.0 and 61.5 %, respectively. The difference between the 
Fig. 1 ROC curve analysis to assess the optimal cutoff value of each pretreatment peripheral blood cell in patients with unresectable advanced 
cervical carcinoma treated with chemoradiotherapy. a ROC curves analysis for ALC at diagnosis; b ROC curves analysis for AMC at diagnosis; c ROC 
curves analysis for LMR at diagnosis. Arrow indicates the pertinent point on the curve that was identified as the better balance between sensitivity 
and specificity. ROC receiver operating characteristic; AMC absolute monocyte count; ALC absolute lymphocyte count; LMR lymphocyte‑to‑mono‑
cyte ratio
Table 2 Univariate analysis of variables associated with 5-year OS and PFS (n = 424)
OS overall survival; PFS progression-free survival; CI confidence interval; LMR lymphocyte-to-monocyte ratio; HPV human papillomavirus; DNA deoxyribonucleic acid; 
HR high risk; FIGO International Federation of Gynecology and Obstetrics; SCC squamous cell carcinoma; ADC adenocarcinoma; ASC adenosquamous carcinoma, UDC 
undifferentiated carcinoma; IC inductive chemotherapy; CCRT concurrent chemoradiotherapy; RT radiation therapy; AMC absolute monocyte count; ALC absolute 
lymphocyte count
Prognostic factors OS PFS
Hazard ratio 95 % CI p value Hazard ratio 95 % CI p value
LMR: high versus low 0.528 0.129–0.849 0.008 0.541 0.136–0.894 0.002
HPV DNA status: HR‑positive HPV DNA versus non‑HR HPV DNA 0.404 0.025–0.647 0.001 0.529 0.151–0.826 0.001
Age : ≤46 versus >46 0.452 0.121–0.837 0.014 0.412 0.087–1.030 0.040
FIGO classification: IIA versus IIB versus IIIA versus IIIB versus  
IIIB versus IVA
0.197 0.018–0.416 0.034 0.484 0.0134–0.839 0.024
pathological type: SCC versus ADC versus ASC versus UDC 0.418 0.168–0.827 0.031 0.478 0.174–0.930 0.043
Lymph node status classification: positive lymph node versus  
negative lymph node
3.586 0.876–5.439 0.043 2.542 1.047–4.283 0.045
Treatment modality: IC + RT versus CCRT versus IC + CCRT 0.530 0.129–0.934 0.039 2.164 1.687–4.017 0.102
ALC: high versus low 0.571 0.292–0.843 0.002 0.513 0.385–0.738 0.008
AMC: high versus low 2.418 1.215–4.738 0.931 0.714 0.306–1.136 0.035
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two groups was significant in terms of the log-rank test 
(p  =  0.000, Fig.  3a). Furthermore, patients in the high 
LMR group had longer PFS than those in the low LMR 
group (p = 0.000, Fig. 3b).
In the HR-positive HPV DNA group, the 5-year OS and 
PFS rates were 82.5 versus 54.8  % (p =  0.032) and 83.9 
versus 50.9 % (p = 0.027) for the high LMR group versus 
the low LMR group before treatment (Fig. 3c, d), respec-
tively. However, for the non-HR HPV DNA group, no sig-
nificant difference in the 5-year OS was found between 
the two groups, with 66.8 and 65.9 % (p > 0.05) (Fig. 3e). 
A tendency of significant difference existed on PFS, with 
72.8 and 57.8 % (p = 0.052, Fig. 3f ).
The 5-year OS and PFS rates were 81.7 versus 58.4  % 
(p  =  0.030) and 82.5 versus 52.0  % (p =  0.032) for the 
HR-positive HPV DNA group versus the non-HR HPV 
DNA group before treatment (Fig. 4a, b), respectively.
Prognostic implications of LMR level and concurrent HPV 
DNA status from pretreatment cancer tissue
Each combined expression of LMR level and concurrent 
HPV DNA status in a single patient before treatment 
formed three different combined groups, namely, high 
LMR/HR-positive HPV DNA, high LMR/non-HR HPV 
DNA or low LMR/HR-positive HPV DNA, and low 
LMR/non-HR HPV DNA group. As shown in Fig. 4c and 
d, patients with high LMR and concurrent HPV-positive 
DNA showed the best prognosis because of their longer 
OS times than any other groups on OS and PFS (p < 0.01, 
both). This group was followed by patients with high 
LMR/non-HR HPV DNA or low LMR/HR-positive HPV 
DNA, and finally by those with low LMR/non-HR HPV 
DNA.
Univariate analysis of variables associated with 5-year OS 
and PFS
In univariate analysis, we revealed that most of clino-
pathological factors (LMR level, HPV DNA status, age, 
FIGO classification, lymph node status classification, and 
ALC) were related to OS, and PFS, respectively, as sum-
marized in Table 2. AMC was not significantly related to 
OS, although it was significantly related to PFS. Contrary 
to AMC, treatment modalities were significantly related 
to OS (HR  =  0.530, 95  % CI 0.129–0.934, p  =  0.039), 
Fig. 2 Kaplan–Meier survival curve for patients with unresectable advanced cervical carcinoma patients according to each pretreatment peripheral 
blood cell. a ALC and OS; b ALC and PFS; c AMC and OS; and d AMC and PFS
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Fig. 3 Kaplan–Meier survival curve for patients with unresectable advanced cervical carcinoma patients according to LMR. a All the enrolled 
patients and OS; b All the enrolled patients and PFS; c HR‑positive HPV DNA group and OS; d HR‑positive HPV DNA group and PFS; e non‑HR HPV 
DNA group and OS; and f non‑HR HPV DNA group and PFS
Page 8 of 14Li et al. Cancer Cell Int  (2016) 16:54 
although they were not significantly related to PFS 
(p = 0.102, Fig. 5).
Multivariate Cox risk model analysis
Some variables proved significant in the univariate anal-
ysis, were further introduced into the Cox regression 
model using the Enter method, revealing that patho-
logical type and HPV DNA status were independent 
predictors of OS, and PFS, respectively, in addition to 
FIGO classification (HR =  3.486, 95  % CI 0.987–5.439, 
p = 0.035) of OS, for all the enrolled patients (Table 3). 
Treatment modalities were independent predictors of 
OS, but not of PFS, whereas ALC were independent pre-
dictors of OS, but not of PFS (Table 3).
For all the enrolled patients, high LMR level was con-
firmed to be an independent prognostic factor for 
superior OS (HR = 0.337, 95 % CI 0.129–0.543, p = 0.001) 
and superior PFS (HR  =  0.239, 95  % CI 0.236–0.593, 
p = 0.001, Table 3).
In the concurrent study, we found that different 
treatment modalities had a positive impact on OS for 
patients with an unresectable advanced cervical carci-
noma who received chemoradiation (Fig. 5b). To reduce 
heterogeneity of the studied cohort, we repeated the 
Cox analysis according to specific treatment modality. 
We found that LMR was still an independent prognos-
tic factor for superior survival for each treatment group 
(Tables 4, 5, 6).
In the multivariate analysis, among the three combined 
modality as mentioned above, the low LMR and concur-
rent non-HR HPV DNA status were the negative prog-
nostic factors for OS (HR = 2.970, 95 % CI 2.075–5.141, 
Fig. 4 Kaplan–Meier survival curve for patients with advanced cervical carcinoma according to HPV DNA status or combined modality based on 
pretreatment LMR level and concurrent HPV DNA status. a HPV DNA status and OS; b HPV DNA status and PFS; c combined modality and OS; and  
d combined modality and PFS
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p =  0.000) and PFS (HR =  1.844, 95 % CI 1.348–2.523, 
p = 0.000), respectively.
Discussion
To the best of our knowledge, this study is the first to 
explore the positive prognostic effect of high LMR on 
survival and its close association with HPV DNA status 
of pretreatment cancer tissue in patients with unresect-
able advanced cervical carcinoma treated with chemo-
radiotherapy. Elevated level of pretreatment ALC and 
HR-positive HPV DNA status were provide to be signifi-
cantly correlated with superior OS and PFS. LMR and 
HPV DNA status were independent prognostic factors, 
and their combined detection can be of better prognostic 
value for OS and PFS, which can be used to stratify 
patients with unresectable advanced cervical carcinoma 
at HR of unfavorable prognosis.
In the last decade, pretreatment peripheral differen-
tial leukocytes (including neutrophil, lymphocyte, and 
monocyte) have been observed to be associated with 
prognosis of various cancers. Survival outcomes in cer-
vical carcinoma patients are influenced by immune 
cells [17, 18] in the tumor microenvironment, including 
tumor-infiltrating lymphocytes and neutrophils. How-
ever, in clinical settings, the prognostic value of the LMR 
and monocytes as well as its correlation with HR-positive 
HPV DNA status have not been elucidated in cervical 
cancer but have been observed in other cancers [19–30].
Fig. 5 Kaplan–Meier survival curve for patients with advanced cervical carcinoma according to treatment modalities. a Treatment modalities and 
PFS; b Treatment modalities and OS
Table 3 Multivariate analysis of  Cox proportional hazards model 5-year of  OS and  PFS for  all the enrolled patients 
(n = 424)
OS overall survival; PFS progression-free survival; CI confidence interval; LMR lymphocyte-to-monocyte ratio; HPV human papillomavirus; DNA deoxyribonucleic acid; 
HR high risk; FIGO International Federation of Gynecology and Obstetrics; SCC squamous cell carcinoma; ADC adenocarcinoma; ASC adenosquamous carcinoma, UDC 
undifferentiated carcinoma; IC inductive chemotherapy; CCRT concurrent chemoradiotherapy; RT radiation therapy; AMC absolute monocyte count; ALC absolute 
lymphocyte count
Prognostic factors OS PFS
Hazard ratio 95 % CI p value Hazard ratio 95 % CI p value
LMR: high versus low 0.337 0.129–0.543 0.001 0.239 0.236–0.593 0.001
HPV DNA status: HR‑positive HPV DNA versus non‑HR HPV DNA 0.243 0.036–0.535 0.001 0.267 0.054–0.772 0.006
Age: ≤46 versus >46 1.591 1.021–3.627 0.065 2.512 1.001–3.872 0.091
FIGO classification: IIA versus IIB versus IIIA versus IIIB versus IIIB versus 
IVA
3.486 0.957–5.248 0.035 3.275 0.845–5.328 0.073
pathological type: SCC versus ADC versus ASC versus UDC 2.523 1.093– 4.486 0.013 2.753 1.964–5.359 0.017
Lymph node status classification: positive versus negative 1.375 0.896–3.247 0.073 2.553 1.587–3.439 0.065
Treatment modality: IC + RT versus CCRT versus IC + CCRT 3. 864 3.587–6.339 0.039 2.486 1.987–4.239 0.102
ALC: high versus low 0.394 0.198–0.624 0.027 0.512 0.165–0.928 0.143
AMC: high versus low 1.703 0.138–3.614 0.181 0.982 0.301–2.124 0.713
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The prognostic influence of lymphocyte and mono-
cyte, as the major components of inflammatory response, 
have been extensively investigated on cancer patients. 
In the current study, the increased circulating lympho-
cyte count (≥2.35  ×  109/L) was closely correlated with 
better OS in unresectable advanced cervical carcinoma 
under univariate and multivariate analysis. This result 
is consistent with the study of Choi et  al. who reported 
that high lymphocyte count (≥2.145 × 109/L) remains an 
independent factor for favorable survival in patients with 
unresectable advanced cervical carcinoma [31]. However, 
ALC failed to maintain its prognostic role in some other 
tumors [24, 32]. No clear data are currently available to 
explain this problem. A possible explanation could be the 
different cutoff values of the absolute lymphocyte count 
observed by different studies. Another possible explana-
tion is that different immune subtypes of lymphocytes 
can have different influences on biological effects and 
prognosis in different tumors, apart from the pure quan-
tity. For example, tumor-infiltrating lymphocytes (TILs) 
establish a defense barrier against cancer, whereas regu-
latory T-cells may have inhibitory effects on antitumor 
immunity. Furthermore, some studies showed that higher 
levels of TILs, including CD8+ T-cells in some cancers, 
are correlated with a favorable survival [33], whereas 
regulatory T cell infiltration in pancreatic carcinoma has 
been found to be an unfavorable prognostic factor [34, 
35].
Table 4 Multivariate analysis of Cox proportional hazards model of 5-year OS and PFS for the patients of the IC + CCRT 
group (n = 134)
OS overall survival; PFS progression-free survival; CI confidence interval; LMR lymphocyte-to-monocyte ratio; HPV human papillomavirus; DNA deoxyribonucleic acid; 
HR high risk; FIGO International Federation of Gynecology and Obstetrics; SCC squamous cell carcinoma; ADC adenocarcinoma; ASC adenosquamous carcinoma; UDC 
undifferentiated carcinoma; IC inductive chemotherapy; CCRT concurrent chemoradiotherapy; RT radiation therapy; AMC absolute monocyte count; ALC absolute 
lymphocyte count
Prognostic factors OS PFS
Hazard ratio 95 % CI p value Hazard ratio 95 % CI p value
LMR: high versus low 0.362 0.181–0.523 0.010 0.329 0.325–0.693 0.018
HPV DNA status: HR‑positive HPV DNA versus non‑HR HPV DNA 0.203 0.025–0. 425 0.001 0.317 0.104–0.672 0.028
Age: ≤46 versus >46 0.532 0.121–0.727 0.063 1.021 0.876–3.672 0.153
FIGO classification: IIA versus IIB versus IIIA versus IIIB versus IIIB versus 
IVA
0.186 0.087–0.439 0.035 0.238 0.0137–0.639 0.033
pathological type: SCC versus ADC versus ASC versus UDC 0.416 0.087–0.539 0.010 0.286 0.187–0.441 0.011
Lymph node status classification: positive lymph node versus negative 
lymph node
1.475 0.987–3.439 0.043 2.753 1.587–4.339 0.045
ALC: high versus low 0.460 0.108–0.732 0.030 0.421 0.265–0.828 0.001
AMC: high versus low 1.814 1.049–3.738 0.131 0.682 0.212–1.225 0.135
Table 5 Multivariate analysis of Cox proportional hazards model of 5-year OS and PFS for the patients of the CCRT group 
(n = 147)
OS overall survival; PFS progression-free survival; CI confidence interval; LMR lymphocyte-to-monocyte ratio; HPV human papillomavirus; DNA deoxyribonucleic acid; 
HR high risk; FIGO International Federation of Gynecology and Obstetrics; SCC squamous cell carcinoma; ADC adenocarcinoma; ASC adenosquamous carcinoma; UDC 
undifferentiated carcinoma; IC inductive chemotherapy; CCRT concurrent chemoradiotherapy; RT radiation therapy; AMC absolute monocyte count; ALC absolute 
lymphocyte count
Prognostic factors OS PFS
Hazard ratio 95 % CI p value Hazard ratio 95 % CI p value
LMR: high versus low 0.251 0.161–0.412 0.013 0.218 0.014–0.582 0.021
HPV DNA status: HR‑positive HPV DNA versus non‑HR HPV DNA 0.132 0.023–0.314 0.001 0.206 0.064–0.516 0.017
Age: ≤46 versus >46 0.323 0.101–0.616 0.072 1.113 0.756–3.561 0.403
FIGO classification: IIA versus IIB versus IIIA versus IIIB versus IIIB versus IVA 0.174 0.074–0.338 0.024 0.127 0.017–0.528 0.023
pathological type: SCC versus ADC versus ASC versus UDC 0.305 0.056–0.428 0.001 0.275 0.126–0.490 0.031
Lymph node status classification: positive lymph node versus negative 
lymph node
1.364 0.789–3.238 0.063 2.531 1.476–4.821 0.059
ALC: high versus low 0.458 0.198–0.824 0.021 0.512 0.165–0.928 0.013
AMC: high versus low 0.703 0.149–1.614 0.219 0.982 0.301–2.124 0.533
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Monocytes, as either inflammatory or immune cells, 
can be mobilized from the bone marrow to the periph-
eral blood and are furtherly prompted into tissue mac-
rophages in the inflammation setting [36]. On this basis, 
macrophages in the tumor microenvironment can accel-
erate cancer-related angiogenesis, invasiveness, immuno-
suppression, and cell seeding metastasis [37, 38]. Patients 
with cervical cancer can be divided into superior- and 
inferior-prognosis subgroups based on pretreatment cir-
culating AMC [39]. These previous studies indicated that 
peripheral blood monocytes may be linked to unfavora-
ble prognosis. However, unlike the previous studies, the 
present study failed to reveal that pretreatment periph-
eral blood AMC showed significant correlation with 
long-time treatment outcome in the setting of unresecta-
ble advanced cervical carcinoma. However, patients with 
HR-positive HPV DNA have higher monocyte counts 
than those with negative HPV DNA. Although various 
mechanisms have yet be confirmed through studies, we 
speculate that higher monocyte counts may be caused by 
the activation and release of virus-derived proinflamma-
tory cytokines, such as GM-CSF, TNF-alpha and IL-12, 
in the inflammation setting.
Pretreatment LMR serves as an independent prognos-
tic factor for survival in some malignancies excluding 
cervical carcinoma [7, 9, 24]. However, the prognostic 
significance of LMR in cervical cancer has not been clari-
fied. The present study is the first to find a positive effect 
of high LMR on survival in unresectable advanced cer-
vical carcinoma. In particular, patients in the high LMR 
group had a significantly longer OS than those in the 
low LMR group (25.0 versus 16.0  months, p  <  0.001), 
for all the enrolled patients. Moreover, high LMR level 
was confirmed to be an independent prognostic factor 
for superior survival (HR = 0.337, 95 % CI 0.129–0.543, 
p < 0.01, Table 3). As is known to us, the different treat-
ment modality may have some effect on treatment out-
come. Similarly, we also found that different treatment 
modality had a positive impact on OS for patients with an 
unresectable advanced cervical carcinoma who received 
chemoradiation (Fig.  5). To reduce heterogeneity of the 
studied cohort, we repeated the Cox analysis according 
to specific treatment modality. We found that LMR was 
an independent prognostic factor for superior survival 
for each treatment group (Tables  4, 5, 6). In the cur-
rent study, we only discussed the favorable prognostic 
impact of high LMR level for patients with an unresect-
able advanced cervical carcinoma. For cervical cancer 
patients who undergo a radical operation, a newer study 
also demonstrated that a decreased pretreatment LMR is 
associated with a poor prognosis [40] patients with stage 
Ib1-IIa cervical cancer. Based on these facts, we could 
conclude that pretreatment high LMR is associated with 
a good prognosis in cervical carcinoma.
In the current study, we found that the similarity of 
clinical implication for these two parameters (pretreat-
ment ALC and LMR) did exist. For example, firstly, ele-
vated level of pretreatment ALC and LMR were provided 
to be significantly correlated with superior OS and PFS 
under an univariate analysis (Table 2); Secondly, like pre-
treatment LMR, ALC was also an independent prognos-
tic factor for OS under multivariate analysis for all the 
enrolled patients (Table 3) or those from each treatment 
group (Tables 4, 5, 6); Thirdly, both ALC and LMR could 
be used to stratify patients at HR of malignancy-related 
death (Figs. 2, 3a, b). However, the differences of clinical 
Table 6 Multivariate analysis of  Cox proportional hazards model of  5-year OS and  PFS for  the patients of  the IC +  RT 
group (n = 143)
OS overall survival; PFS progression-free survival; CI confidence interval; LMR lymphocyte-to-monocyte ratio; HPV human papillomavirus; DNA deoxyribonucleic acid; 
HR high risk; FIGO International Federation of Gynecology and Obstetrics; SCC squamous cell carcinoma; ADC adenocarcinoma; ASC adenosquamous carcinoma; UDC 
undifferentiated carcinoma; IC inductive chemotherapy; CCRT concurrent chemoradiotherapy; RT radiation therapy; AMC absolute monocyte count; ALC absolute 
lymphocyte count
Prognostic factors OS PFS
Hazard ratio 95 % CI p value Hazard ratio 95 % CI p value
LMR: high versus low 0.471 0.229–0.634 0.010 0.430 0.436–0.794 0.027
HPV DNA status: HR‑positive HPV DNA versus non‑HR HPV DNA 0.314 0.036–0.536 0.012 0.418 0.215–0.738 0.039
Age: ≤46 versus >46 0.643 0.232–0.837 0.074 1.132 0.987–3.783 0.264
FIGO classification: IIA versus IIB versus IIIA versus IIIB versus IIIB versus 
IVA
0.297 0.198–0.540 0.045 0.395 0.0245–0.740 0.044
pathological type: SCC versus ADC versus ASC versus UDC 0.527 0.186–0.640 0.036 0.397 0.298–0.552 0.023
Lymph node status classification: positive lymph node versus negative 
lymph node
2.586 0.987–4.540 0.073 2.753 1.747–5.394 0.065
ALC: high versus low 0.548 0.098–0.931 0.012 0.589 0.065–0.938 0.015
AMC: high versus low 0.829 0.152–1.730 0.321 0.771 0.413–2.313 0.421
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implication for these two parameters were also observed. 
Firstly, the former had sensitivity of 77.73 % and specific-
ity of 72.4 % as a predictor of OS, whereas the latter had 
sensitivity of 85.37 % and specificity of 75.40 % (Fig. 1a, 
c). Secondly, previous study demonstrated that several 
conditions, such as chronic inflammatory diseases, active 
infection, and smoking, may influence the specificity of 
both markers [41], although ALC and AMC are easy to 
measure. LMR superiority is due to the stability of the 
ratio compared with the absolute cell counts [42]. Based 
on the reasons mentioned above, we concluded that LMR 
is more accurate than ALC as a predictor in cervical 
carcinoma.
Previous studies have demonstrated that the hyperacti-
vation of the inflammatory pathways subsequent to viral 
infection is a driving force that accelerates cancer devel-
opment, malignant traits, and progression of cervical 
cancer [43, 44]. Moreover, previous data demonstrated 
that negative HPV is linked to poor prognosis in invasive 
cervical cancer [11]. Similar with most previous results, 
this study also found that patients in the HR-positive 
HPV DNA group showed higher 5-year OS and PFS rates 
than those in the non-HR HPV DNA group. Moreover, 
HPV DNA status was an independent prognostic factor 
for PFS and OS (Table 2).
We classified the enrolled patients according to the 
detected HPV DNA status from pretreatment cancer 
tissue, in order to elucidate the influence of HPV DNA 
status on the prognosis of LMR level in cervical cancer. 
We observed that higher LMR level was an independent 
prognostic factor for superior survival in the HR-positive 
HPV DNA group. In the non-HR HPV DNA group, the 
findings were contrary to those in the HR-positive HPV 
DNA group. No significant difference on PFS and OS was 
found between the two groups, thereby supporting the 
concept that the prognostic effect of LMR in advanced 
cervical carcinoma may be correlated with the HPV DNA 
status.
We further investigated the clinical value of joint detec-
tion of pretreatment LMR level and HPV DNA status in 
a single patient. Patients with high LMR and concurrent 
HR-positive HPV DNA showed the best prognostic fac-
tor because of their longer survival compared with other 
groups on OS and PFS (p < 0.01, both). Moreover, high 
LMR and concurrent HR-positive HPV DNA were found 
to be independent predictive markers of OS.
This study has several limitations given its retrospective 
nature. First, selection bias cannot be completely elimi-
nated in the study cohort. Therefore, caution should be 
taken while interpreting the results of this study. Second, 
during stratified analysis, the sample size was too small 
to provide sufficiently persuasive evidence to support any 
given conclusion. Based on these limitations, a prospec-
tive study should be conducted to provide more evidence 
to support the conclusions of this study.
Conclusions
This study is the first to demonstrate that pretreatment 
elevated peripheral blood LMR can predict favorable 
prognosis and is an independent prognostic factor for OS 
and PFS in locally advanced cervical cancer, along with 
HR-HPV DNA status. The different effects of LMR in 
combined chemoradiotherapy on survival may be related 
to the HR-HPV DNA status of pretreatment cancer tis-
sue in patients with locally advanced cervical carcinoma. 
The combined detection of LMR and HR-HPV DNA sta-
tus can contribute in the correct stratification of patients 
with unresectable advanced cervical carcinoma at HR of 
unfavorable prognosis. We acknowledge that this finding 
is limited to a retrospective study in a single center. Thus, 
further studies are necessary to be performed in a multi-
center or prospective manner to validate these important 
findings.
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